Антигипертензивная эффективность валсартана, влияние на состояние центральной гемодинамики и микроциркуляции: взгляд с позиций органопротекции
Abstract
About the Authors
В. ПодзолковRussian Federation
В. Булатов
Russian Federation
Е. Сон
Russian Federation
В. Маколкин
Russian Federation
References
1. Guidelines Subcommittee. 1999 World Health Organization – International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83.
2. Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Первый доклад экспертов Научного общества по изучению артериальной гипертонии, Всероссийского научного общества кардиологов и Межведомственного совета по сердечно - сосудистым заболеваниям (ДАГ-1). РМЖ 2000; 8: 318–46.
3. Chobanian A.V, Bakris G.L, Cushman W.C et al. The Seventh Report of the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003; 289: 2560–72.
4. Guidelines Subcommittee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
5. Thurmann P.A, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.
6. Dahlof B, Zanchetti A, Diez J et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855–64.
7. Brenner B, Cooper M, de Zeeuw D et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
8. Viberti G, Wheeldon N.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure - independent effect. Circulation 2002; 106: 672–8.
9. Maggioni A.P, Anand I, Gottlieb S.O et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin - converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414–21.
10. Levy B.I. Microcirculation in hypertension. A new target for treatment? Circulation 2001; 104: 735–40.
11. Struijker Boudier H.A.J. Hypertension and the microcirculation. In: Kaplan N., ed. Hypertension, microcirculation and end organ damage. London.; Lippincott Williams & Wilkins. 2002: 49–55.
12. Маколкин В.И., Подзолков В.И., Павлов В.И., Самойленко В.В. Состояние микроциркуляции при гипертонической болезни. Кардиология 2003; 5: 60–7.
13. Isoyama S. Coronary vasculature in hypertrophy. In: Sheridan D.J, ed. Left Ventricular Hypertrophy, 1st ed. London.; Churchill Ltd; 1998: 29–36.
14. Strauer B.E. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol 1990; 65: 34G–41G.
15. Yudkin J.S, Forrest R.D, Jackson C.A. Microalbumiuria as predictor of vascular disease in non - diabetic subjects. Islington. Diabetes Surv. Lancet 1988; 2: 530–3.
16. Baumbach G.L, Heistad D.D. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989; 13: 968–72.
17. Gavras H, Brunner H.R. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension 2001; 37 (Pt.2): 342–5.
18. Simon G., Illyes G. Structural vascular changes in hypertension. Role of angiotensin II, dietary sodium supplementation, and sympathetic stimulation, alone and in combination in rats. Hypertension 2001; 37: 255–60.
19. Бранько В.В., Вахляев В.Д., Камшилина Л.С., Маколкин В.И. Применение метода лазерной допплеровской флоуметрии в кардиологии. Росс. мед. журн. 1998; 3: 34–8.
20. Маколкин В.И., Бранько В.В., Богданова Э.А. Метод лазерной допплеровской флоуметрии в кардиологии. М., 1999.
21. Маколкин В.И., Подзолков В.И., Павлов В.И., Богданова Э.А., Камшилина Л.С., Самойленко В.В. Состояние микроциркуляции при гипертонической болезни. Кардиология 2002; 7: 36–40.
22. Oparil S, Dyke S, Harris F et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797–810.
23. Pool J, Oparil S, Hedner T et al. Dose - responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20: 1106–14.
24. Neutel J, Weber M, Pool J et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–58.
Review
For citations:
, , , . Systemic Hypertension. 2004;(1):40-43.